KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Buildings (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has 6 years of Buildings data on record, last reported at $1.4 billion in Q4 2017.

  • For Q4 2017, Buildings rose 12.77% year-over-year to $1.4 billion; the TTM value through Dec 2017 reached $1.4 billion, up 12.77%, while the annual FY2017 figure was $1.4 billion, 12.77% up from the prior year.
  • Buildings reached $1.4 billion in Q4 2017 per REGN's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, Buildings topped out at $1.4 billion in Q4 2017 and bottomed at $343.4 million in Q4 2013.
  • Average Buildings over 5 years is $844.5 million, with a median of $760.5 million recorded in 2015.
  • Peak YoY movement for Buildings: surged 90.61% in 2015, then increased 12.77% in 2017.
  • A 5-year view of Buildings shows it stood at $343.4 million in 2013, then grew by 16.2% to $399.0 million in 2014, then soared by 90.61% to $760.5 million in 2015, then skyrocketed by 68.08% to $1.3 billion in 2016, then rose by 12.77% to $1.4 billion in 2017.
  • Per Business Quant database, its latest 3 readings for Buildings were $1.4 billion in Q4 2017, $1.3 billion in Q4 2016, and $760.5 million in Q4 2015.